Ameriprise’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.09M | Buy |
240,451
+112,242
| +88% | +$1.57M | ﹤0.01% | 2685 |
|
|
2026
Q1 | $1.64M | Buy |
128,209
+54,683
| +74% | +$697K | ﹤0.01% | 3045 |
|
|
2025
Q4 | $661K | Buy |
73,526
+23,879
| +48% | +$329K | ﹤0.01% | 3520 |
|
|
2025
Q3 | $857K | Buy |
49,647
+37,844
| +321% | +$466K | ﹤0.01% | 3433 |
|
|
2025
Q2 | $111K | Buy |
11,803
+1,443
| +14% | +$11.8K | ﹤0.01% | 3875 |
|
|
2025
Q1 | $73.7K | Sell |
10,360
-21,349
| -67% | -$216K | ﹤0.01% | 3913 |
|
|
2024
Q4 | $370K | Buy |
31,709
+529
| +2% | +$8.26K | ﹤0.01% | 3642 |
|
|
2024
Q3 | $641K | Sell |
31,180
-4,791
| -13% | -$110K | ﹤0.01% | 3399 |
|
|
2024
Q2 | $804K | Buy |
35,971
+3,851
| +12% | +$91.7K | ﹤0.01% | 3242 |
|
|
2024
Q1 | $884K | Sell |
32,120
-277,092
| -90% | -$7.7M | ﹤0.01% | 3218 |
|
|
2023
Q4 | $9.43M | Buy |
309,212
+275,857
| +827% | +$7.93M | ﹤0.01% | 1831 |
|
|
2023
Q3 | $1.05M | Buy |
33,355
+16,602
| +99% | +$644K | ﹤0.01% | 3119 |
|
|
2023
Q2 | $683K | Buy |
16,753
+266
| +2% | +$10.8K | ﹤0.01% | 3321 |
|
|
2023
Q1 | $614K | Sell |
16,487
-394,335
| -96% | -$15.5M | ﹤0.01% | 3345 |
|
|
2022
Q4 | $14.3M | Sell |
410,822
-24,154
| -6% | -$1.15M | ﹤0.01% | 1446 |
|
|
2022
Q3 | $24.3M | Buy |
434,976
+20,819
| +5% | +$1.29M | 0.01% | 1062 |
|
|
2022
Q2 | $21.4M | Sell |
414,157
-18,003
| -4% | -$914K | 0.01% | 1168 |
|
|
2022
Q1 | $31.4M | Sell |
432,160
-5,330
| -1% | -$452K | 0.01% | 1032 |
|
|
2021
Q4 | $51.7M | Buy |
437,490
+713
| +0.2% | +$89.3K | 0.01% | 828 |
|
|
2021
Q3 | $58.6M | Buy |
436,777
+219,321
| +101% | +$33.2M | 0.02% | 694 |
|
|
2021
Q2 | $35.2M | Buy |
217,456
+202,813
| +1,385% | +$15.8M | 0.01% | 967 |
|
|
2021
Q1 | $1.22M | Buy |
14,643
+6,490
| +80% | +$436K | ﹤0.01% | 3064 |
|
|
2020
Q4 | $312K | Buy |
+8,153
| New | +$296K | ﹤0.01% | 3494 |
|
|
2019
Q4 | – | Sell |
-11,281
| Closed | -$150K | – | 3745 |
|
|
2019
Q3 | $150K | Sell |
11,281
-23,570
| -68% | -$376K | ﹤0.01% | 3601 |
|
|
2019
Q2 | $570K | Buy |
34,851
+23,057
| +195% | +$362K | ﹤0.01% | 3284 |
|
|
2019
Q1 | $202K | Buy |
+11,794
| New | +$176K | ﹤0.01% | 3554 |
|
|
2018
Q4 | – | Sell |
-94,381
| Closed | -$2.7M | – | 3733 |
|
|
2018
Q3 | $2.7M | Sell |
94,381
-9,640
| -9% | -$280K | ﹤0.01% | 2690 |
|
|
2018
Q2 | $2.76M | Buy |
+104,021
| New | +$2.52M | ﹤0.01% | 2589 |
|
Other funds holding NTLA
Ameriprise's NTLA Position: Q2 2026 in Review
Ameriprise increased its Intellia Therapeutics (NTLA) stake by 88% in Q2 2026, buying an estimated $1.57M and bringing the position to 240,451 shares worth $4.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2685.
Ameriprise first reported a position in NTLA in Q2 2018 and has held it in 28 quarters since. The position peaked at $58.6M in Q3 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Ameriprise held 240,451 shares of Intellia Therapeutics worth $4.09M as of Q2 2026.
- Ameriprise bought 112,242 Intellia Therapeutics shares in Q2 2026, an estimated $1.57M.
- Intellia Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2685 holding.
- Ameriprise first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 28 quarters since.
- Ameriprise's Intellia Therapeutics position peaked at $58.6M in Q3 2021.
- 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.